<DOC>
	<DOCNO>NCT02107287</DOCNO>
	<brief_summary>Considering promise result hypofractionated low intermediate risk prostate cancer , proposal translate experience patient high risk prostate cancer . Patients high risk disease would receive hypofractionated RT prostate external internal iliac lymph node use IMRT plus long-term hormonal therapy . The objective study show long term grade &gt; 2 late toxicity acceptable similar publish data use hypofractionated technique prostate .</brief_summary>
	<brief_title>Hypofractionated Intensity Modulated Radiation Therapy Plus Hormonal Therapy Patients With High Risk Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>pathologically proven diagnosis adenocarcinoma prostate meet one follow condition : Clinical Stage &gt; T3 Gleason Score 8 high , PSA level &gt; 20ng/ml Study entry PSA must obtain within 6 week prior protocol entry ECOG &lt; 2 Age &gt; 18 History physical examination within 3 month Bone scan CT scan abdomen pelvis within 3 month evidence bone metastases pelvic lymph node large 1.0cm , unless biopsy negative . CBC differential within 6 week prior protocol entry Absolute neutrophil count &gt; 2000cells/mm3 Hemoglobin &gt; 8.0 g/dl ( use transfusion increase Hg acceptable ) Testosterone level within 6 week protocol entry Liver function test Signed informed consent Prior use hormonal therapy prostate cancer acceptable le 2 month . Prior use hormonal therapy prostate cancer 2 month . Previous use finasteride dutasteride allow . Prior invasive malignancy ( except nonmelanoma skin ) unless diseasefree 5 year . Prior radiotherapy pelvis Life expectancy le 2 year .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>